What Researchers Did
Researchers retrospectively reviewed medical records of 169 patients with osteoradionecrosis (ORN) to assess outcomes of medical management using pentoxifylline, tocopherol (PENTO) or PENTO plus clodronate (PENTOCLO).
What They Found
Medical management resulted in healed ORN in 54.4% (92 out of 169) of patients over an average of 12.9 months. The PENTO regimen was significantly superior to PENTOCLO (p = 0.0001), and healing was inversely related to ORN severity (p < 0.0001). Patients who healed required significantly fewer antibiotic prescriptions (1.3) compared to those with disease progression (4.3).
What This Means for Canadian Patients
This medical approach could offer a non-surgical treatment option for Canadian patients with osteoradionecrosis, particularly for less severe or non-infected cases. It may help stabilize the condition even when complete healing is not achieved, potentially reducing the need for more invasive interventions.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or with Canadian participants.
Study Limitations
As a retrospective study, it is limited by its reliance on existing medical records and the potential for selection bias.